YESAFILI

targets

all catalysts(2)

News(10)

• This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
  The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
  biopharma_dive · 1d ago
• Lilly, Foghorn part ways; Wave’s FDA-approved plans
  The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
  biopharma_dive · 2d ago
• Kodiak skyrockets on positive study data for 2 eye drugs
  The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
  biopharma_dive · 5d ago
• Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
  Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
  endpoints · 5d ago
• Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
  Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.
  biospace · 5d ago
• STAT+: AbbVie wins FDA nod for Parkinson’s pill
  The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug helped improve symptoms.
  stat · 5d ago
• Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
  Two of Kodiak Sciences’ drug candidates have matched aflibercept in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.
  fiercebiotech · 5d ago
• Merck sees pivotal victory for $3B eye disease prospect
  Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
  fiercebiotech · 9d ago
• Regeneron to challenge Ipsen as FDA clears bone disease drug
  Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
  biopharma_dive · 1mo ago
• EyePoint’s bid to compete with Eylea falls flat
  EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial. The company’s shares {$EYPT…
  endpoints · 1mo ago